Protox completes prostate cancer trial recruitment

---

Protox Therapeutics Inc. completes recruitment of patients for its Phase I study of PRX302 to treat localized, recurrent prostate cancer. The company is on track to report top line data from this study by mid year.

"This is a significant milestone for Protox as we march towards our goal of providing a safe and effective treatment for millions of men suffering with localized prostate cancer," said Dr. Fahar Merchant, president and CEO of Protox Therapeutics. "We are looking forward to delivering top line data from this trial shortly and expect to initiate a Phase II clinical trial before the end of the year."

PRX302 is a targeted pro-drug that turns into a potent anti-cancer agent once it is activated by prostate specific antigen (PSA), which is produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX302 selectively destroys the cells by punching holes in the cell membrane.